(0.32%) 5 116.03 points
(0.31%) 38 358 points
(0.36%) 15 986 points
(-1.00%) $83.01
(5.36%) $2.03
(0.29%) $2 354.10
(0.37%) $27.64
(4.13%) $960.20
(-0.26%) $0.932
(-0.44%) $10.98
(-0.58%) $0.796
(1.66%) $93.40
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 7.96%
@ $4.90
発行日: 15 2月 2024 @ 05:50
リターン: -39.02%
前回のシグナル: 2月 15 - 03:56
前回のシグナル:
リターン: 2.30 %
Live Chart Being Loaded With Signals
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer...
Stats | |
---|---|
本日の出来高 | 839 063 |
平均出来高 | 2.31M |
時価総額 | 509.61M |
EPS | $0 ( 2024-03-14 ) |
次の収益日 | ( $-0.390 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.430 |
ATR14 | $0.00600 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-22 | Moore Timothy L. | Sell | 17 360 | Common Stock |
2024-03-14 | Chang David D | Sell | 53 393 | Common Stock |
2024-01-30 | Parker Geoffrey M. | Buy | 190 | Common Stock |
2024-01-25 | Moore Timothy L. | Buy | 341 515 | Stock Option (Right to buy) |
2024-01-25 | Moore Timothy L. | Buy | 96 600 | Common Stock |
INSIDER POWER |
---|
93.40 |
Last 94 transactions |
Buy: 32 219 312 | Sell: 32 079 170 |
ボリューム 相関
Allogene Therapeutics Inc 相関
10 最も負の相関 | |
---|---|
SKYA | -0.962 |
LEGA | -0.957 |
BRIV | -0.955 |
ADAL | -0.953 |
TBSAU | -0.951 |
TBSA | -0.95 |
CRZN | -0.949 |
LDHA | -0.949 |
FTPA | -0.949 |
AGGR | -0.949 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Allogene Therapeutics Inc 相関 - 通貨/商品
Allogene Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $95 000.00 |
総利益: | $-242.82M (-255 598.95 %) |
EPS: | $-2.09 |
FY | 2023 |
収益: | $95 000.00 |
総利益: | $-242.82M (-255 598.95 %) |
EPS: | $-2.09 |
FY | 2022 |
収益: | $243 000 |
総利益: | $-16.49M (-6 783.95 %) |
EPS: | $-2.30 |
FY | 2021 |
収益: | $38.49M |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.14 |
Financial Reports:
No articles found.
Allogene Therapeutics Inc
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。